Skip to main content
. 2021 May 4;33(3):254–262. doi: 10.5021/ad.2021.33.3.254

Table 3. Summary of the adverse events.

Adverse event After the first laser treatment After the second laser treatment After the third laser treatment
Erythema 22 (100) 20 (90.9) 22 (100)
Transient 20 (90.9) 20 (90.9) 22 (100)
(17/3/0) (12/8/0) (13/9/0)
Persistent 2 (9.1) 0 0
(0/2/0)†
Pruritus 19 (86.4) 16 (72.7) 17 (77.3)
Transient 15 (68.2) 13 (59.1) 16 (72.7)
(10/5/0) (9/4/0) (14/2/0)
Persistent 4 (18.2) 3 (13.6) 1 (4.5)
(1/3/0) (1/2/0) (0/1/0)
Petechiae 13 (59.1) 14 (63.6) 13 (59.1)
Transient 10 (45.5) 11 (50.0) 13 (59.1)
(9/1/0) (8/3/0) (10/3/0)
Persistent 3 (13.6) 3 (13.6) 0 (0)
(2/1/0)† (2/1/0)
Pustules 12 (54.5) 5 (22.7) 5 (22.7)
Transient 7 (31.8) 4 (18.2) 3 (13.6)
(5/2/0) (4/0/0) (2/1/0)
Persistent 5 (22.8) 1 (4.5) 2 (9.1)
(4/1/0) (1/0/0) (0/2/0)
Papules 0 (0%) 1 (4.5) 0 (0)
Transient 0 1 (4.5) 0
(1/0/0)
Persistent 0 0 0

Transient adverse events resolved in 1 to 3 days; persistent adverse event persisted for >3 days. Values are presented as number (%) or number only. Indicates (mild/moderate/severe case number).